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TB Drug Resistance 
in the U.S.
Tuberculosis (TB) is a serious respiratory disease caused by bacteria that are spread from person to person through the 
air. In most cases, TB is treatable and curable; however, TB can be deadly without proper treatment.
TB bacteria can become resistant to the drugs used for treatment. When this occurs, treatment is often still possible, but it 
is complex, long, challenging, and expensive.  
Rates of drug-resistant TB remain relatively low in the United States, though nearly half a million cases are estimated to 
occur globally each year.1 These cases underscore the need for ongoing vigilance and action, especially given the ease 
with which TB can spread through international travel and migration.
The Centers for Disease Control and Prevention works with state and local health departments and other health care 
providers to prevent the spread of TB, track drug-resistant cases, assist with diagnosis as needed, and help ensure that 
patients with drug-resistant TB receive effective treatment and care.
Causes of TB Drug Resistance
Drug-resistant TB can occur when the drugs used to treat TB are misused or mismanaged. This may happen when:
n    A patient misses doses or does not complete the full course of treatment
n    A health care provider prescribes the wrong treatment, wrong dose, or wrong length of time for taking the drugs
n    Effective drugs are not available
n    Drugs are of poor quality
Individuals with drug-resistant TB disease can also transmit the resistant strain of the disease directly to others.
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Multidrug-Resistant TB (MDR TB)
MDR TB is a type of TB that is resistant to at least two of the best and most important anti-TB drugs: isoniazid and 
rifampin. These two drugs are considered first-line drugs and are recommended for treatment of all persons with drug-
susceptible TB disease (i.e., cases that are not drug resistant).
While MDR TB is often curable, treatment is complex, 
requiring expert management and frequent monitoring.  
In comparison with drug-susceptible TB, which takes  
about six to 12 months to treat, treatment for MDR TB 
can take up to 24 months and requires the use of second-
line medicines that are not as effective as the first-line 
medicines commonly prescribed to treat TB. The second-
line medicines may also produce side effects that are 
difficult to tolerate. Close monitoring of patients while 
taking these drugs is critical, because the treatments 
can lead to other serious health problems, such as liver 
damage, hearing loss, changes in vision, behavioral 
changes (including psychosis), or affect heart function.  
Treatment for MDR TB costs an average of $131,000, 
compared with $17,000 to treat drug-susceptible TB.4  
MDR TB is relatively rare in the United States. The 
proportion of U.S. TB cases that are MDR TB has remained 
relatively stable at approximately 1 percent in recent 
years. Among all TB cases with drug-susceptibility testing 
completed, MDR TB accounted for 1.2 percent (83 cases) 
in 2012.3
Globally, it is estimated that nearly one in 25 new TB cases (3.6 percent) and one in five previously treated cases (20 
percent) are MDR TB.1 India, China, and the Russian Federation account for more than half of the world’s total cases of 
MDR TB, but the highest proportion of cases that are MDR TB occur in Eastern Europe and Central Asia. 
The majority of U.S. MDR TB cases (86 percent) occur among foreign-born individuals.3 Most of these individuals were 
likely infected prior to their arrival in the United States, reflecting the heavy burden of TB outside this country. CDC is 
collaborating with other national and international public health organizations to improve TB screening and treatment of 
immigrants and refugees from countries with high rates of disease prior to entry in the U.S.
Drug-Resistant TB
n   Multidrug-Resistan t TB (MDR TB): TB that is 
resistant to at least two of the best and most 
important anti-TB drugs (isoniazid and rifampin). 
While treatment is complicated, MDR TB is often 
curable.
n   Ex tensively Drug-Resistant TB (XDR TB): TB 
that is resistant to isoniazid and rifampin, and 
to second-line treatments including any one of 
the fluoroquinolones and at least one of three 
injectable drugs. Treatment options are very 
limited and outcomes are often worse.
  
Extensively Drug-Resistant TB (XDR TB)
XDR TB is a rare type of multidrug-resistant tuberculosis. It is resistant to isoniazid and rifampin, and to second-line treatments 
including any one of the fluoroquinolones and at least one of three injectable drugs (amikacin, kanamycin, or capreomycin).
XDR TB can be treated and cured, but treatment options are less effective, have serious side effects, and are very 
expensive. In a recent CDC study, the average cost to treat a person in the U.S. with XDR TB was $430,000.4 Additionally, 
XDR TB is more likely to lead to death.
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XDR TB remains very rare in the United States; only two cases were reported in 2012.3 Globally, however, XDR TB presents 
the greatest threat to TB control. WHO reported that 92 countries worldwide had at least one case of XDR TB by the end 
of 2012, and an estimated 10 percent of MDR TB cases worldwide are XDR TB.1 
TB Drug Shortages
Shortages of drugs used to treat TB have been reported 
over the past several years and are of particular concern.  
Often these shortages involve second-line TB drugs, 
which are critical for treating drug-resistant cases. In a 
2010 survey, 81 percent of health departments with MDR 
TB cases reported difficulty obtaining these second-line 
treatments.5  
Drug shortages put patients and communities at greater 
risk for illness and death. These shortages can disrupt 
treatment in patients and further the development of 
drug resistance. This can also prolong the infectiousness 
of a patient and therefore increase the risk of transmission 
to the community. And when less effective regimens 
must be used for treatment, this ultimately leads to worse 
patient outcomes.
For example, in April 2011, shortages of two second-line 
drugs caused an eight-day delay in treatment of a father 
and infant who had MDR TB.5 This prolonged the father’s 
infectious period, increasing the risk of transmission to 
the community. While both were ultimately successfully 
treated, the delay particularly endangered the health of 
the infant, who could have faced severe brain damage  
or death.
Ongoing collaboration among CDC, the U.S. Food and 
Drug Administration (FDA), health departments, national 
health societies, and the pharmaceutical industry is  
critical in order to ensure the availability of effective  
anti-TB drugs.
TB Basics
n    Not everyone infected with TB bacteria becomes 
sick.  Most people who breathe in TB bacteria 
and become infected are able to fight the disease 
and stop the bacteria from growing. This is 
called latent TB infection. People with latent 
TB infection do not feel sick, do not have any 
symptoms, and cannot spread the bacteria to 
others. 
n    In some people, TB bacteria overwhelm the 
defenses of the immune system and begin to 
multiply, resulting in the progression from latent 
TB infection to TB disease. Without treatment, 
the bacteria continue to multiply and destroy the 
body’s tissue. At this stage, TB bacteria may be 
spread to others.  
n    According to the World Health Organization 
(WHO), about one-third of the world’s population 
has latent TB infection6 and nearly nine million 
people developed TB disease in 2012.1   
n    In the United States, cases of TB disease have 
been declining for 20 years (to fewer than 10,000 
in 2012)3, but more than 11 million people in this 
country are estimated to have latent TB infection 
with the potential to develop TB disease.2 Asian 
Americans, blacks, and Hispanics are more 
affected by TB than whites. People living with 
HIV and people who are homeless are especially 
vulnerable to TB.
n   T reatment for TB disease typically requires 
multiple medications that must be taken for 
several months.
Preventing Drug-Resistant TB
The most effective way to combat drug-resistant TB is to 
prevent it from occurring in the first place. Both patients 
and health care providers have a role to play in this.
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Patients should:
n    Take all medications exactly as prescribed and finish the full course of treatment, even if they no longer feel sick
n    Tell their health care provider if they are having trouble taking medications
Health care providers should:
n    Diagnose TB cases quickly and accurately, including detection of drug resistance
n    Follow recommended treatment guidelines
 –    Directly observed therapy is the most effective way to ensure that a patient with TB disease is taking 
medication and to determine if the medication is properly treating the disease
n    Monitor patients’ responses to treatment
n    Ensure therapy is completed
CDC is helping by:
n    Conducting ongoing monitoring and surveillance to track drug-resistant cases
n    Supporting state and local health departments with diagnosis and drug-susceptibility testing, as well as assisting  
with the development of treatment regimens for challenging cases 
n    Providing training and education materials and resources for state and local TB control programs and other  
health care providers
n    Providing funding to all 50 states, 8 territories, and 10 major cities to support local TB elimination activities, such as 
ensuring patients finish their treatment and that individuals exposed to TB disease are evaluated  
If you are a member of the news media and need more information, please visit www.cdc.gov/nchhstp/Newsroom
or contact the News Media Line at CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention 
(404-639-8895 or NCHHSTPMediaTeam@cdc.gov).
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